"High Content Review" interviews Michelle Arkin about the ADDC

Date: 09 December 2013


Introducing the Academic Drug Discovery Consortium (ADDC)
Last year HCR posted Outsourcing HCS: a summary of some options a lab
might consider if they are contemplating a high content screen. Since then a group of directors from university based drug discovery centers have formed the Academic Drug Discovery Consortium (ADDC), www.addconsortium.org.

The goal of the ADDC is to build a collaborative network among university-led drug discovery centers, their research and funding partners, and related CROs and other stakeholders. There is a comment in the new Nature Reviews Drug Discovery called Bringing together the academic drug discovery community that goes into detail about the driving forces behind this new organization. To learn more, HCR caught up with Michelle Arkin, Associate Director of the Small Molecule Discovery Center at the University of California and Founder and Board Member of the ADDC.

Source: HCR Review

Announcement web link